Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17482957rdf:typepubmed:Citationlld:pubmed
pubmed-article:17482957lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:17482957lifeskim:mentionsumls-concept:C0376358lld:lifeskim
pubmed-article:17482957lifeskim:mentionsumls-concept:C0194810lld:lifeskim
pubmed-article:17482957lifeskim:mentionsumls-concept:C0040085lld:lifeskim
pubmed-article:17482957lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:17482957lifeskim:mentionsumls-concept:C0237881lld:lifeskim
pubmed-article:17482957lifeskim:mentionsumls-concept:C0220901lld:lifeskim
pubmed-article:17482957lifeskim:mentionsumls-concept:C0750502lld:lifeskim
pubmed-article:17482957lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:17482957lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:17482957pubmed:issue5lld:pubmed
pubmed-article:17482957pubmed:dateCreated2007-5-7lld:pubmed
pubmed-article:17482957pubmed:abstractTextThymidylate synthase (TS), a key enzyme in DNA synthesis, is overexpressed in a variety of cancer cells. 5-Fluorouracil (5-FU), an anticancer agent used clinically against various cancers, including prostate cancer, inhibits DNA synthesis by binding TS. In this study, we investigated the expression of TS in prostate cancer and its prognostic significance. Its association with the expression of dihydropyrimidine dehydrogenase (DPD), a principal enzyme in the degradation of 5-FU and pyrimidine nucleotides, was also examined.lld:pubmed
pubmed-article:17482957pubmed:languageenglld:pubmed
pubmed-article:17482957pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17482957pubmed:citationSubsetIMlld:pubmed
pubmed-article:17482957pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17482957pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17482957pubmed:statusMEDLINElld:pubmed
pubmed-article:17482957pubmed:monthMaylld:pubmed
pubmed-article:17482957pubmed:issn1527-9995lld:pubmed
pubmed-article:17482957pubmed:authorpubmed-author:FukushimaMasa...lld:pubmed
pubmed-article:17482957pubmed:authorpubmed-author:MizutaniYoich...lld:pubmed
pubmed-article:17482957pubmed:authorpubmed-author:KawauchiAkihi...lld:pubmed
pubmed-article:17482957pubmed:authorpubmed-author:MikiTsuneharu...lld:pubmed
pubmed-article:17482957pubmed:authorpubmed-author:UkimuraOsamuOlld:pubmed
pubmed-article:17482957pubmed:authorpubmed-author:SakaiToshiyuk...lld:pubmed
pubmed-article:17482957pubmed:authorpubmed-author:NonomuraNorio...lld:pubmed
pubmed-article:17482957pubmed:authorpubmed-author:OkiharaKojiKlld:pubmed
pubmed-article:17482957pubmed:authorpubmed-author:ShiraishiTaku...lld:pubmed
pubmed-article:17482957pubmed:authorpubmed-author:YongnanLiLlld:pubmed
pubmed-article:17482957pubmed:issnTypeElectroniclld:pubmed
pubmed-article:17482957pubmed:volume69lld:pubmed
pubmed-article:17482957pubmed:ownerNLMlld:pubmed
pubmed-article:17482957pubmed:authorsCompleteYlld:pubmed
pubmed-article:17482957pubmed:pagination988-95lld:pubmed
pubmed-article:17482957pubmed:meshHeadingpubmed-meshheading:17482957...lld:pubmed
pubmed-article:17482957pubmed:meshHeadingpubmed-meshheading:17482957...lld:pubmed
pubmed-article:17482957pubmed:meshHeadingpubmed-meshheading:17482957...lld:pubmed
pubmed-article:17482957pubmed:meshHeadingpubmed-meshheading:17482957...lld:pubmed
pubmed-article:17482957pubmed:meshHeadingpubmed-meshheading:17482957...lld:pubmed
pubmed-article:17482957pubmed:meshHeadingpubmed-meshheading:17482957...lld:pubmed
pubmed-article:17482957pubmed:meshHeadingpubmed-meshheading:17482957...lld:pubmed
pubmed-article:17482957pubmed:meshHeadingpubmed-meshheading:17482957...lld:pubmed
pubmed-article:17482957pubmed:meshHeadingpubmed-meshheading:17482957...lld:pubmed
pubmed-article:17482957pubmed:meshHeadingpubmed-meshheading:17482957...lld:pubmed
pubmed-article:17482957pubmed:meshHeadingpubmed-meshheading:17482957...lld:pubmed
pubmed-article:17482957pubmed:meshHeadingpubmed-meshheading:17482957...lld:pubmed
pubmed-article:17482957pubmed:meshHeadingpubmed-meshheading:17482957...lld:pubmed
pubmed-article:17482957pubmed:meshHeadingpubmed-meshheading:17482957...lld:pubmed
pubmed-article:17482957pubmed:meshHeadingpubmed-meshheading:17482957...lld:pubmed
pubmed-article:17482957pubmed:meshHeadingpubmed-meshheading:17482957...lld:pubmed
pubmed-article:17482957pubmed:meshHeadingpubmed-meshheading:17482957...lld:pubmed
pubmed-article:17482957pubmed:meshHeadingpubmed-meshheading:17482957...lld:pubmed
pubmed-article:17482957pubmed:meshHeadingpubmed-meshheading:17482957...lld:pubmed
pubmed-article:17482957pubmed:meshHeadingpubmed-meshheading:17482957...lld:pubmed
pubmed-article:17482957pubmed:meshHeadingpubmed-meshheading:17482957...lld:pubmed
pubmed-article:17482957pubmed:meshHeadingpubmed-meshheading:17482957...lld:pubmed
pubmed-article:17482957pubmed:year2007lld:pubmed
pubmed-article:17482957pubmed:articleTitlePrognostic significance of thymidylate synthase expression in patients with prostate cancer undergoing radical prostatectomy.lld:pubmed
pubmed-article:17482957pubmed:affiliationDepartment of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan.lld:pubmed
pubmed-article:17482957pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17482957pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:17482957pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17482957lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17482957lld:pubmed